reason report
solid minim covid impact guidanc trial intact
result beat consensu revenu ep
estim reaffirm guidanc minor
downward revis capital-expenditure suggest rel consist
outlook year despit disrupt total
product sale y/i flat q/q beat consensu
larg in-lin forecast total revenu doubl digit y/i
growth primarili result one-tim boost otezla first full
quarter otezla sale reach consensu
lower forecast otezla strong perform suggest
increment use patient arent abl receiv iv infus
doctor offic due disrupt overal saw
materi disrupt commerci product although product
requir in-offic treatment inevit impact even
prolia/xgeva major surpris compani
legaci product continu erod face continu gener
biosimilar competit despit perform compani
emerg product continu price pressur suggest
reliant otezla early-stag oncolog pipelin provid
meaning acceler compani growth trajectori
oper expens lower consensu
estim despit y/i increas driven otezla-rel
cost oper margin improv percentag point driven
strong product sale rel lower expens guidanc
oper margin provid compani expect maintain
competit margin high single-digit growth oper expens
net result non-gaap ep beat
consensu estim
manag expect major delay key pipelin
program result covid includ monotherapi
studi non-smal cell lung cancer nsclc tezepelumab asthma
phase omecamtiv mecarbil phase data avail
end year upcom american societi clinic
oncolog present updat phase
data kra inhibitor colorect cancer
solid tumor type believ data could offer addit
insight depth durabl respons data
addit tumor type could also provid sens opportun
less-preval tumor type kra express occur
averag dcf price-to-earnings p/sale
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million dilut non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
reflect current market condit pt reiter mp
base latest sale trend manag commentari
disclosur revenu forecast remain larg unchang
next year revenu forecast nearli in-lin latest
consensu oper expens estim
moder increas reflect increas
cost associ pipelin develop otezla commerci
non-gaap ep estim lower next year
latest consensu base chang
estim chang peer compani multipl increas
price target reiter market perform rate amgen
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
view unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
revenu larg without major surpris impact limit
total revenu higher consensu in-lin forecast product
sale flat q/q increas y/i higher consensu
lower estim yoy total product sale volum growth unit
inventori off-set declin net sell price sale grew yoy
driven volum growth off-set net price foreign exchang
headwind manag see limit pandem impact product portfolio except product
requir in-offic treatment vulner elderli patient even prolia
enbrel sale lower consensu forecast enbrel y/i
growth nearli flat posit inventori sale adjust off-set neg net price
lower demand neulasta sale continu declin eros yoy qoq
driven biosimilar competit neg impact volum net sell price also
includ one-tim order global neulasta sale nearli flat
compar consensu forecast indic exit share
long-act segment onpro exit share
sensipar sale increment lower collaps earli part due
continu gener competit revenu declin yoy moder
sequenti basi qoq grew sole driven price increas
hematology/oncolog product sale grew strongli despit impact total sale
increas y/i q/q primarili driven unit growth amgen main
kyproli y/i blincyto y/i imlyg sale report separ
posit momentum biosimilar product continu kanjinti sale
increas qoq mvasi sale increas qoq amgevita grow qoq
newer product aimovig sale grew yoy decreas qoq significantli
miss estim consensu despit expand demand aimovig
sale neg impact net price decreas due expand coverag
repatha came estim consensu
sale repres yoy growth driven increas unit volum
off-set net price decreas although net sell price declin yoy manag
indic price appear remain rel stabl qoq
bone portfolio even prolia far busi impact given
patient age vulner accord manag commentari even sale increas
forecast despit beat versu consensu
product aimovig repatha even continu key contributor top line growth
manag seem excit addit otezla sale
consensu indic otezla investig potenti
immunomodulatori therapi expect time acquisit otezla
seem like provid major net revenu growth
non-gaap ep significantli consensu estim
amgen oper expens consensu estim despit
y/i increas driven otezla-rel cost oper margin improv percentag
point driven strong product sale rel lower expens guidanc
oper margin provid compani expect retain competit margin high
single-digit growth oper expens non-gaap tax rate slightli lower
estim consensu non-gaap dilut share count
suggest on-going share repurchas compani throughout year
remain net result non-gaap ep beat consensu
estim
manag re-affirmed guidanc revenu guidanc rang
bracket consensu adjust ep guidanc bracket
estim consensu adjust tax rate guidanc
bracket consensu estim higher estim
compani reduc capital-expenditure guidanc higher
estim consensu estim manag outlook
remain larg unchang despit disrupt top-lin growth
like come recent acquir otezla
major delay key pipelin program enthusiasm center around
otezla
manag expect major delay key pipelin program includ
monotherapi studi nsclc tezepelumab asthma phase omecamtiv mecarbil
phase data avail end year upcom present
updat phase data kra inhibitor solid tumor
type believ data could offer addit insight depth durabl
respons european societi medic oncolog esmo data show
orr diseas control rate across dose level data addit tumor
type could also provid sens opportun less-preval tumor type
kra express occur remain optimist prospect otezla
compani expect data phase studi mild-to-moder psoriasi
compani also suggest make progress on-going develop bite
program expect disclos first in-human data readout bcma hle bite
second half year
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock celg
sni rhhbi gsk nv price sale multipl larg cap
biotechnolog pharma compani novo nv
discount cash flow dcf use rel multipl larg cap biopharma compani
ep appli ep estim give one year
futur valu use establish larg cap futur revenu multipl sale
appli revenu forecast give futur valu final
dcf valuat base current outlook compani exist product
probability-weight revenu contribut late-stag pipelin program discount
compani wacc give fair valu today averag three
approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
sale
interest expens incom net
non-gaap incom tax
share count period dilut
guidanc
late stage pipelin program includ
late stage pipelin program exclud
brand
updat result phase dose escal studi
updat result phase dose escal studi non nsclc
mild moder psoriasi
phase result mild moder psoriasi
initi phase trial patient elev lp level
initi phase result combin
proof concept data
phase result hfref
svb leerink llc equiti research compani file
type event
event trial detail
date known
up/down
expect
least six month
end
end
svb leerink llc equiti research compani file
phase data readout
phase data readout
phase data expect
await updat clinic hold
await first clinic data
await updat phase data
await updat clinic hold
await updat develop plan
phase studi begin
million
corp partner revenue incl royalti
po probabl success fda approv
sbv leerink llc research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
sbv leerink llc research compani file
analysi stock price svb leerink target
method model larg cap healthcar growth stock ep multipl ep
appli amgen ep
svb leerink updat ep estim
current averag ep multipl consensu ep compar slow
grow us eu larg cap biopharma stock sni rhhbi
impli target price ep
revenu multipl appli svb leerink revenu forecast
svb leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price revenu use us biopharma comp
method dcf adjust debt declin flow
stabl termin cash flow growth discount wacc
present valu flow termin valu
averag method
svb leerink llc research compani file factset
